Chemistry:Motolimod
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C28H34N4O2 |
| Molar mass | 458.606 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Motolimod (VTX-2337) is a drug which acts as a potent and selective agonist of toll-like receptor 8 (TLR8), a receptor involved in the regulation of the immune system. It is used to stimulate the immune system, and has potential application as an adjuvant therapy in cancer chemotherapy, although clinical trials have shown only modest benefits.[1][2] It also worsens neuropathic pain in animal models and has been used to research the potential of targeting TLR8 in some kinds of chronic pain syndromes.[3][4]
See also
- Imiquimod
- Vesatolimod
References
- ↑ "A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study". Annals of Oncology 28 (5): 996–1004. May 2017. doi:10.1093/annonc/mdx049. PMID 28453702.
- ↑ "Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial". JAMA Oncology 4 (11): 1583–1588. November 2018. doi:10.1001/jamaoncol.2018.1888. PMID 29931076.
- ↑ "TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG". The Journal of Experimental Medicine 215 (12): 3019–3037. December 2018. doi:10.1084/jem.20180800. PMID 30455267.
- ↑ "TLR8 in the Trigeminal Ganglion Contributes to the Maintenance of Trigeminal Neuropathic Pain in Mice". Neuroscience Bulletin. December 2020. doi:10.1007/s12264-020-00621-4. PMID 33355900.
 |  |
